Financing ·
Trinity Biotech enters $4.35M ATM agreement with Lucid Capital Markets after terminating prior program
TRIBTrinity Biotech PLC
On June 12, 2026, Trinity Biotech plc entered into an At the Market (ATM) Offering Agreement with Lucid Capital Markets, LLC to sell up to $4,352,314 of its American Depositary Shares (ADSs). Lucid will receive a commission of 3.0% of the gross sales price. Additionally, on June 2, 2026, the company terminated its previous ATM program with Craig-Hallum Capital Group LLC, which had been inactive since March 2025. Trinity Biotech plc operates in the healthcare industry and develops and manufactures diagnostic products.